Paula Green Sells 297 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 297 shares of the business’s stock in a transaction on Friday, September 20th. The stock was sold at an average price of $46.94, for a total value of $13,941.18. Following the completion of the transaction, the senior vice president now directly owns 87,895 shares in the company, valued at approximately $4,125,791.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Paula Green also recently made the following trade(s):

• On Monday, August 5th, Paula Green sold 1,137 shares of Twist Bioscience stock. The shares were sold at an average price of $39.93, for a total value of $45,400.41.
• On Tuesday, July 2nd, Paula Green sold 322 shares of Twist Bioscience stock. The stock was sold at an average price of $48.00, for a total value of $15,456.00.

Twist Bioscience Trading Down 1.7 %

Twist Bioscience stock opened at $45.67 on Thursday. The firm has a market cap of $2.68 billion, a price-to-earnings ratio of -13.59 and a beta of 1.76. The stock has a fifty day simple moving average of $46.59 and a two-hundred day simple moving average of $43.22. Twist Bioscience Co. has a 12 month low of $14.42 and a 12 month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The business had revenue of $81.50 million during the quarter, compared to the consensus estimate of $77.40 million. During the same period in the previous year, the business posted ($1.01) EPS. The firm’s revenue for the quarter was up 27.7% on a year-over-year basis. On average, equities research analysts forecast that Twist Bioscience Co. will post -3.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on TWST. The Goldman Sachs Group upped their target price on Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, July 9th. Guggenheim began coverage on Twist Bioscience in a research report on Tuesday, June 4th. They set a “buy” rating and a $53.00 price objective on the stock. Barclays dropped their target price on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 5th. Robert W. Baird increased their price objective on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a report on Monday, August 5th. Finally, JPMorgan Chase & Co. increased their price objective on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $48.22.

Institutional Trading of Twist Bioscience

Several large investors have recently modified their holdings of the company. American International Group Inc. grew its holdings in shares of Twist Bioscience by 0.8% in the first quarter. American International Group Inc. now owns 28,506 shares of the company’s stock worth $978,000 after acquiring an additional 213 shares during the period. Caprock Group LLC lifted its position in Twist Bioscience by 2.9% during the second quarter. Caprock Group LLC now owns 7,851 shares of the company’s stock valued at $387,000 after purchasing an additional 220 shares in the last quarter. Arizona State Retirement System lifted its position in Twist Bioscience by 1.9% during the second quarter. Arizona State Retirement System now owns 16,187 shares of the company’s stock valued at $798,000 after purchasing an additional 308 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in Twist Bioscience by 3.5% during the second quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company’s stock valued at $457,000 after purchasing an additional 312 shares in the last quarter. Finally, CWM LLC lifted its position in Twist Bioscience by 27.4% during the second quarter. CWM LLC now owns 2,437 shares of the company’s stock valued at $120,000 after purchasing an additional 524 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.